SEC Form 8-K Summary
Registrant: MedTech Acquisition Corporation; the request metadata identifies Trisalus Life Sciences, Inc., but the filing names MedTech Acquisition Corporation as the registrant.
Reporting date: December 2, 2022. The filing reports amendments to sponsor promissory notes and does not present operating results for Trisalus or MedTech.
Business Context and Reporting Period
MedTech Acquisition Corporation is a special purpose acquisition company with securities listed on Nasdaq under MTACU, MTAC, and MTACW. The company previously issued unsecured promissory notes to its sponsor, MedTech Acquisition Sponsor LLC, for working capital purposes.
Material Agreement and Financial Obligations
- On December 30, 2021, the company issued a $544,000 unsecured promissory note to the sponsor.
- On January 28, 2022, the company issued a separate $400,000 unsecured promissory note to the sponsor.
- On December 2, 2022, both notes were amended to clarify that principal will not be payable if the company fails to complete its initial business combination by the 24-month anniversary of its initial public offering, or by an applicable extended date under its amended and restated certificate of incorporation.
- All other terms of the notes remain unchanged, according to the filing.
- The filing treats the amended notes as direct financial obligations under Item 2.03.
Revenue, Profit, Cash Flow, Liquidity, and Other Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, cash balance, liquidity, or other operating performance metrics. The disclosed note principal totals $944,000.
Outlook, Risks, and Unusual Items
The amendment links repayment of the sponsor notes to completion of the company’s initial business combination within the applicable deadline. This creates a material contingency concerning repayment if the business combination is not completed by the required date. The filing provides no additional guidance, transaction status, or management outlook.
Important Facts to Verify
- Confirm the applicable 24-month business-combination deadline and any permitted extension under the company’s governing documents.
- Review Exhibit 10.1 for the precise amended repayment language and any other note provisions.
- Verify whether the company completed or subsequently extended its initial business combination.
- Reconcile the filing’s registrant, MedTech Acquisition Corporation, with the requested company name, Trisalus Life Sciences, Inc.
- Assess whether any later filings disclose repayment, conversion, forgiveness, or further amendment of the $944,000 in sponsor notes.